☰
✕
Home/ Healthcare/ Asia Pacific Congenital Heart Diseases Market
Request for TOC Request for Sample
BUY NOW

Asia-Pacific Congenital Heart Disease Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Healthcare | Published Report | Feb 2026 | Asia-Pacific | 350 Pages | No of Tables: 449 | No of Figures: 39
Buy Now Request for Sample
Nucleus

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Asia Pacific Congenital Heart Diseases Market

Market Size in USD Billion

CAGR :  %

USD 1.39 Billion USD 2.63 Billion 2025 2033
Forecast Period
 2026 –2033
Market Size(Base Year)
USD 1.39 Billion
Market Size (Forecast Year)
 USD 2.63 Billion
CAGR
 %
Major Markets Players
  • Medtronic
  • Edwards Lifesciences Corporation
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Terumo Corporation

Asia-Pacific Congenital Heart Disease Market, By Product Type (Treatment and Diagnostic), Disease Type (Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease and Complex Congenital Heart Defects), Age Group (Adults With Congenital Heart Disease, Neonates and Infants (0–1 Years), Children (1–12 Years) and Adolescents (13–18 Years)), End User (Hospitals, Pediatric Cardiac Centers, Specialty Clinics, Diagnostic Laboratories, Research & Academic Institutes, Homecare Settings and Other End Users), Distribution Channel (Direct Tender, Wholesale Distributors, Retail Sales, Online Sales and Others) - Industry Trends and Forecast to 2033

Asia-Pacific Congenital Heart Disease Market Size

  • The Asia-Pacific congenital heart disease market size was valued at USD 1.39 billion in 2025 and is expected to reach USD 2.63 billion by 2033, at a CAGR of 8.4% during the forecast period

  • Congenital heart disease (CHD) refers to structural or functional abnormalities of the heart present at birth, which can affect blood flow, oxygenation, and overall cardiovascular function. The management of CHD involves both treatment (surgical interventions, catheter-based procedures, and pharmacological therapies) and diagnostic methods (imaging, echocardiography, and genetic testing) to detect, monitor, and correct these abnormalities

  • CHD encompasses a spectrum of conditions, including acyanotic congenital heart disease, cyanotic congenital heart disease, and complex congenital heart defects, affecting patients across all age groups from neonates and infants to children, adolescents, and adults

Get Exclusive Sample Copy of this Report Here
Get Exclusive Sample Copy of this Report Here

Asia-Pacific Congenital Heart Disease Market Analysis

  • The Asia-Pacific Congenital Heart Disease market is experiencing steady growth, driven by the rising prevalence of congenital heart defects, increasing adoption of minimally invasive cardiac procedures, and growing awareness of early diagnosis and timely intervention

  • Healthcare systems across the region are undergoing continuous modernization, with public and private investments focused on expanding pediatric and cardiac care units, improving surgical and interventional outcomes, and reducing procedure-related complications. As conditions such as acyanotic congenital heart disease, cyanotic congenital heart disease, and complex congenital heart defects become more widely recognized, the demand for effective diagnostic and treatment solutions has increased, creating sustained market opportunities

  • China dominated the Asia-Pacific congenital heart disease market with the largest revenue share of 34.11% in 2025, supported by advanced healthcare infrastructure, strong government and private investments, high adoption of innovative medical technologies, and widespread availability of specialized medical equipment.

  • India is expected to be the fastest-growing country in the Asia-Pacific congenital heart disease market during the forecast period, driven by increasing urbanization, rising healthcare spending, growing access to modern healthcare facilities, and increasing adoption of advanced medical technologies.

  • The treatment segment dominated the largest market revenue share of 65.95% in 2025, driven by the rising demand for early disease detection and continuous patient monitoring across hospitals and clinics.

Get Exclusive Sample Copy of this Report Here

Report Scope and Asia-Pacific Congenital Heart Disease Market Segmentation 

Attributes

Asia-Pacific Congenital Heart Disease Key Market Insights

Segments Covered

  • By Product Type: Treatment and Diagnostic

  • By Disease Type: Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease and Complex Congenital Heart Defects

  • By Age Group: Adults With Congenital Heart Disease, Neonates and Infants (0–1 Years), Children (1–12 Years) and Adolescents (13–18 Years)

  • By End User: Hospitals, Pediatric Cardiac Centers, Specialty Clinics, Diagnostic Laboratories, Research & Academic Institutes, Homecare Settings and Other End Users

  • By Distribution Channel: Direct Tender, Wholesale Distributors, Retail Sales, Online Sales and Others

Countries Covered

Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Australia

  • Thailand

  • Indonesia

  • Philippines

  • Rest of Asia-Pacific

Key Market Players

  • Medtronic (U.S.)

  • Edwards Lifesciences Corporation (U.S.)

  • Abbott Laboratories (U.S.)

  • Boston Scientific Corporation (U.S.)

  • Terumo Corporation (Japan)

  • Siemens Healthineers (Germany)

  • Philips Healthcare (Netherlands)

  • GE Healthcare (U.S.)

  • Lepu Medical Technology (China)

  • Meril Life Sciences Pvt. Ltd. (India)

  • Narang Medical Limited (India)

  • Advacare Pharma (India)

  • Shanghai Microport Scientific Corporation (China)

  • W. L. Gore & Associates, Inc. (U.S.)

  • B. Braun SE (Germany)

  • LivaNova PLC (U.K.)

  • OsCOR Inc. (U.S.)

  • LifeTech Scientific (China)

  • Artivion (formerly CryoLife) (U.S.)

  • Pfizer Inc. (U.S.)

  • AstraZeneca PLC (U.K.)

  • Bristol-Myers Squibb (BMS) (U.S.)

  • Sun Pharmaceutical Industries Ltd. (India)

  • Novartis AG (Switzerland)

Market Opportunities

  • Integration of Artificial Intelligence in Imaging Interpretation and Risk Stratification

  • Scale-Up Of Minimally Invasive Transcatheter Therapies

  • Increased Government Funding and Public-Private Partnerships

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asia-Pacific Congenital Heart Disease Market Trends

“Integration of Artificial Intelligence in Imaging Interpretation and Risk Stratification”

  • The integration of artificial intelligence (AI) into imaging interpretation and risk stratification presents a significant growth opportunity for the Asia-Pacific congenital heart disease market by enhancing diagnostic accuracy, reducing interpretation time, and improving clinical decision support across diverse healthcare settings

  • AI driven tools can analyse medical images — especially echocardiograms and cardiac scans — with high precision, assisting clinicians in detecting subtle structural abnormalities that might otherwise be missed, and enabling earlier diagnosis and risk assessment for congenital heart defects (CHDs)

  • As AI technologies are increasingly validated in research and piloted in clinical programs, public health systems in the region stand to benefit from more efficient workflows, standardized interpretation, and the potential to extend advanced diagnostic capabilities into under resourced hospitals and rural areas.

  • These developments not only improve patient outcomes but also support broader adoption of advanced imaging platforms and predictive models, thereby fostering market expansion in diagnostics and risk stratification solutions across the Asia-Pacific

  • These technology trends support the expansion of diagnostic services and risk assessment solutions, strengthening the overall market ecosystem for congenital heart disease care in the Asia-Pacific

Asia-Pacific Congenital Heart Disease Market Dynamics

Driver

“Rising Prevalence of Congenital Heart Defects in Newborns”

  • The increasing prevalence and enhanced detection rates of congenital heart defects (CHDs) among newborns across the Asia-Pacific region are significant market drivers for the congenital heart disease ecosystem

  • CHDs are among the most common birth defects, and regional health studies and screening programs in populous countries such as China, India, and Indonesia have reported substantial caseloads and expanding detection coverage in recent years, reflecting a sustained demand for early diagnostics, specialized pediatric cardiology services, echocardiography systems, and interventional treatment solutions

  • Enhanced surveillance, newborn screening programs, and government-supported interventions have led to a larger pool of identified cases requiring medical care and follow-up, expanding market opportunities for screening technologies, diagnostic imaging, pediatric cardiac surgery, and long-term patient management solutions throughout Asia-Pacific

  • Furthermore, rising government investments in healthcare infrastructure, improved reimbursement policies, and adoption of smart hospital systems are further accelerating the market

  • These trends are driven both by true increases in diagnosed incidence and by policy-led improvements in case identification and newborn health registries

  • In Jul 2025, Tempo reported that Indonesia’s Health Minister said approximately 12,000 babies annually need congenital heart surgery, but only around 6,000 receive it, resulting in about 6,000 annual deaths from congenital heart defects, highlighting a large and unmet clinical need for expanded cardiac care resources

  • The documented rise in identified congenital heart disease cases and expansion of newborn screening and diagnostic programmes across the Asia-Pacific region underscores an escalating regional health burden that directly feeds demand for congenital heart disease diagnostics, interventional tools, and treatment services

Restraint/Challenge

“High Cost for the Treatment of Congenital Heart Disease”

  • The high cost associated with the diagnosis, surgical intervention, device therapy, and long-term management of congenital heart disease (CHD) remains a significant restraint for market growth across the Asia-Pacific region

  • Treatment of CHD often requires complex open-heart surgeries, advanced interventional procedures, prolonged hospital stays, and lifelong follow-up care, all of which impose substantial financial burdens on families and public healthcare systems

  • In many Asia-Pacific countries, limited insurance coverage, out-of-pocket healthcare expenditure, and uneven access to subsidized pediatric cardiac care restrict timely treatment, particularly in low- and middle-income populations

  • Even where public schemes exist, funding gaps, long waiting lists, and high per-procedure costs constrain procedural volumes.

  • These cost pressures limit adoption of advanced devices and technologies, delay care pathways, and ultimately act as a structural restraint on the expansion of the congenital heart disease market in the region

Get Exclusive Sample Copy of this Report Here

Asia-Pacific Congenital Heart Disease Market Scope

The Asia-Pacific Congenital Heart Disease market is segmented into five notable categories on the basis of product type, disease type, age group, end user, and distribution channel.

  •  By Product Type

On the basis of product type, the Asia-Pacific Congenital Heart Disease market is segmented into diagnostic and treatment solutions. In 2026, the treatment segment is expected to dominate the market with a market share of 66.05%, driven by rising chronic disease prevalence, demand for minimally invasive therapies, and advancements in personalized therapeutic equipment like cardiovascular stents, orthopedic implants, and infusion systems.

The treatment segment is anticipated to witness the fastest CAGR of 8.5% from 2026 to 2033, fueled by the growing burden of chronic and lifestyle-related diseases, rapid adoption of minimally invasive and catheter-based interventions, and continuous technological innovation in implantable and drug-delivery devices.

  •  By Disease Type

On the basis of disease type, the Asia-Pacific congenital heart disease market is segmented into acyanotic congenital heart disease, cyanotic congenital heart disease, and complex congenital heart defects. In 2026, the acyanotic congenital heart disease segment is expected to dominate the Asia-Pacific congenital heart disease market with a market share of 51.40% driven by higher prevalence due to genetic and environmental factors, improved neonatal screening and early diagnosis capabilities, and expanding access to minimally invasive treatments like transcatheter closures for defects such as atrial septal defects (ASD) and ventricular septal defects (VSD).

The complex congenital heart defects segment is expected to witness the fastest CAGR of 8.7% from 2026 to 2033, driven by advancements in hybrid surgical-interventional procedures, increasing survival rates of neonates with severe conditions like hypoplastic left heart syndrome (HLHS) and tetralogy of Fallot, and rising demand for specialized devices such as Melody valves and covered stents.

  •  By Age Group

On the basis of age group, the Asia-Pacific congenital heart disease market is segmented into neonates and infants (0–1 years), children (1–12 years), adolescents (13–18 years), and adults with congenital heart disease. In 2026, the adults with congenital heart disease segment is expected to dominate the Asia-Pacific Congenital Heart Disease market with a market share of 34.46% fueled by improved childhood survival rates leading to a growing adult survivor population, rising awareness of lifelong complications like arrhythmias and heart failure, and increasing demand for specialized follow-up care such as implantable defibrillators and pulmonary hypertension therapies.

The adults with congenital heart disease segment is anticipated to witness the fastest CAGR of 8.8% from 2026 to 2033, driven by the expanding population of long-term survivors from improved pediatric interventions, heightened risks of secondary conditions like arrhythmias and pulmonary hypertension requiring ongoing device-based management, and greater emphasis on multidisciplinary ACHD programs offering advanced therapies such as leadless pacemakers and tricuspid valve interventions.

  •  By End User

On the basis of end user, the market is segmented into hospitals, pediatric cardiac centers, specialty clinics, diagnostic laboratories, research & academic institutes, homecare settings, and other end users. In 2026, the hospitals segment is expected to dominate the Asia-Pacific Congenital Heart Disease market with a market share of 59.22% driven by their advanced infrastructure for complex cardiac surgeries and catheterizations, concentration of specialized pediatric and adult cardiologists, and high-volume access to cutting-edge diagnostic tools like 3D echocardiography and intraoperative imaging.

The pediatric cardiac centers segment is expected to witness the fastest CAGR of 9.1% from 2026 to 2033, fueled by the rapid expansion of specialized facilities in high-prevalence regions like China and India, government-backed initiatives to upgrade neonatal and infant care infrastructure, and surging demand for dedicated centers equipped with hybrid cath labs and fetal cardiac programs.

  • By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, retail sales, online sales, wholesale distributors, and others. In 2026, the direct tender segment is expected to dominate the Asia-Pacific congenital heart disease market with a market share of 52.83% driven by bulk procurement preferences of major hospitals and pediatric cardiac centers for high-cost devices like septal occluders and stents, stringent regulatory standardization ensuring quality and pricing transparency, and government-mandated centralized purchasing in countries like China and India to optimize healthcare budgets.

The online sales segment is expected to witness the fastest CAGR of 8.8% from 2026 to 2033, fueled by rapid digitalization of healthcare procurement platforms in Asia-Pacific, growing adoption of e-commerce portals by private clinics and smaller hospitals for CHD devices like monitoring tools and accessories, and enhanced supply chain efficiencies offering competitive pricing and faster delivery.

Get Exclusive Sample Copy of this Report Here

Asia-Pacific Congenital Heart Disease Market Regional Analysis

  • China dominated the Asia-Pacific congenital heart disease market with the largest revenue share of 34.11% in 2025.

  • Supported by advanced healthcare infrastructure, strong government and private investments, high adoption of innovative medical technologies, and widespread availability of specialized medical equipment

  • The region benefits from a technologically inclined population, robust regulatory frameworks, and well-established healthcare delivery systems, which together facilitate the adoption of advanced medical devices across hospitals, clinics, and diagnostic centers

Get Exclusive Sample Copy of this Report Here

China Congenital Heart Disease Market Insight

China accounted for the largest revenue share within North America in 2025, driven by its massive population base, leading to high CHD birth prevalence, significant government investments in pediatric cardiac infrastructure like the Healthy China 2030 initiative, and rapid expansion of advanced treatment centers performing high volumes of transcatheter and surgical interventions.

India Congenital Heart Disease Market Insight

India is projected to expand at a substantial CAGR throughout the forecast period, driven by its burgeoning population and rising CHD incidence rates, massive government healthcare schemes like Ayushman Bharat enhancing access to pediatric cardiac surgeries, and fast-growing private hospital networks equipped with hybrid cath labs for minimally invasive repairs.

Japan Congenital Heart Disease Market Insight

Japan is expected to grow at a noteworthy CAGR during the forecast period, driven by its advanced healthcare system supporting lifelong ACHD management, aging survivor population from high pediatric survival rates, and strong national health insurance coverage for innovative devices like next-generation valves and monitoring implants. Technological leadership in robotic-assisted CHD surgeries, expanding specialized adult congenital heart programs in urban centers, and proactive government screening policies further accelerate Japan's steady market expansion in the Asia-Pacific congenital heart disease landscape.

Asia-Pacific Congenital Heart Disease Market Share

The Asia-Pacific Congenital Heart Disease industry is primarily led by well-established companies, including:

  • Medtronic (U.S.)

  • Edwards Lifesciences Corporation (U.S.)

  • Abbott Laboratories (U.S.)

  • Boston Scientific Corporation (U.S.)

  • Terumo Corporation (Japan)

  • Siemens Healthineers (Germany)

  • Philips Healthcare (Netherlands)

  • GE Healthcare (U.S.)

  • Lepu Medical Technology (China)

  • Meril Life Sciences Pvt. Ltd. (India)

  • Narang Medical Limited (India)

  • Advacare Pharma (India)

  • Shanghai Microport Scientific Corporation (China)

  • W. L. Gore & Associates, Inc. (U.S.)

  • B. Braun SE (Germany)

  • LivaNova PLC (U.K.)

  • OsCOR Inc. (U.S.)

  • LifeTech Scientific (China)

  • Artivion (formerly CryoLife) (U.S.)

  • Pfizer Inc. (U.S.)

  • AstraZeneca PLC (U.K.)

  • Bristol-Myers Squibb (BMS) (U.S.)

  • Sun Pharmaceutical Industries Ltd. (India)

  • Novartis AG (Switzerland)

Latest Developments in Asia-Pacific Congenital Heart Disease Market

  • In June 2025, Medtronic announced the launch of the Micra AV2 and VR2, the world’s smallest leadless pacemakers, in India. These are designed to last longer, work better, and make life easier for patients with slow heart rhythms. The Micra AV2 and VR2 are the latest innovations in the Medtronic Micra leadless pacemaker family. They do not have leads or require a chest incision, which helps avoid potential complications, like infections, that can happen with traditional pacemakers with leads.

  • In September 2024, Medtronic plc expands the capabilities of Medtronic Customer eXperience Center (MCXC) in Singapore with the opening of its first Robotics Experience Studio in Southeast Asia. This underscores the commitment of Medtronic to enhance access to new technologies through collaboration, training, and education within the healthcare ecosystem

  • In December 2025, the FDA approved Edwards Lifesciences' SAPIEN M3 Mitral Valve replacement system as the first transseptal transcatheter therapy.

  • In October 2025, Abbott announced the launch of the AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world. This tiny high-tech device is implanted through a minimally invasive procedure directly inside the heart to help it beat properly, without wires (leads) or surgical pockets used in traditional pacemakers.

  • In August 2025, Boston has initiated the AGENT DCB STANCE clinical trial to compare its Agent drug‑coated balloon (DCB) directly with standard PCI treatment using drug‑eluting stents or balloon angioplasty in patients with de novo coronary lesions.

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC CONGENITAL HEART DISEASE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END-USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSSIS

4.2 PORTERS FIVE FORCES ANALYSIS

4.3 COST ANALYSIS BREAKDOWN

4.3.1 INTRODUCTION

4.3.2 CONGENITAL HEART DISEASE COST STRUCTURE OVERVIEW

4.3.2.1 DIAGNOSTIC & IMAGING COST BREAKDOWN

4.3.2.2 SURGICAL TREATMENT COST BREAKDOWN

4.3.2.3 INTERVENTIONAL TREATMENT COST BREAKDOWN

4.3.2.4 HOSPITALIZATION & PROCEDURE COSTS

4.3.2.5 MEDICATION & LONG-TERM CARE COSTS

4.3.3 COST BREAKDOWN BY HOSPITAL TIER

4.3.4 REGIONAL COST VARIATION

4.3.5 MARKET IMPLICATIONS

4.3.6 CONCLUSION

4.4 INDUSTRY INSIGHTS

4.4.1 MICRO AND MACRO ECONOMIC FACTORS

4.4.2 PENETRATION AND GROWTH PROSPECT MAPPING

4.4.3 INTERVIEWS WITH SPECIALISTS

4.4.4 ANALYSIS AND RECOMMENDATION

4.5 INNOVATION TRACKER AND STRATEGIC ANALYSIS

4.5.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

4.5.1.1 JOINT VENTURES

4.5.1.2 MERGERS AND ACQUISITIONS

4.5.1.3 LICENSING AND PARTNERSHIP

4.5.1.4 TECHNOLOGY COLLABORATIONS

4.5.1.5 STRATEGIC DIVESTMENTS.

4.5.2 NUMBER OF PRODUCTS IN DEVELOPMENT

4.5.3 STAGE OF DEVELOPMENT

4.5.4 TIMELINES AND MILESTONES

4.5.5 INNOVATION STRATEGIES AND METHODOLOGIES

4.5.6 RISK ASSESSMENT AND MITIGATION

4.5.7 FUTURE OUTLOOK

4.6 NUMBERS OF CONGENITAL HEART DISEASE PATIENT IN EACH COUNTRY

4.7 PATENT ANALYSIS

4.7.1 PATENT QUALITY AND STRENGTH

4.7.2 COUNTRY PATENT LANDSCAPE

4.7.3 IP STRATEGY AND MANAGEMENT

4.7.4 LICENSING AND COLLABORATION

4.8 PREMIUM CLINICAL & COMMERCIAL INSIGHTS:

4.8.1 PATIENT ACCESS

4.8.2 PATIENT DIAGNOSE SITUATION

4.8.3 OPERATION NUMBERS OF CHD PATIENTS

4.8.4 OPERATION NUMBERS OF THE TOP TIER HOSPITAL

4.8.5 TOP SURGEON NAMES

4.8.6 PRODUCT PRICING (AVERAGE SELLING PRICE IN USD)

4.8.6.1 DIAGNOSTIC & IMAGING SYSTEMS

4.8.6.2 SURGICAL DEVICES

4.8.6.3 INTERVENTIONAL DEVICES

4.8.6.4 MEDICATION

 

4.9 TECHNOLOGY ROADMAP

4.9.1 INTRODUCTION

4.9.2 CURRENT TECHNOLOGY LANDSCAPE (2024–2026)

4.9.2.1 SURGICAL TECHNOLOGIES

4.9.2.2 INTERVENTIONAL DEVICES

4.9.2.3 SUPPORTIVE AND MONITORING TECHNOLOGIES

4.9.2.4 DIGITAL AND DATA-DRIVEN TOOLS

4.9.3 EMERGING TECHNOLOGIES (2026–2030)

4.9.4 FUTURE TECHNOLOGY TRAJECTORY (2030+)

4.9.5 STRATEGIC TAKEAWAYS FOR STAKEHOLDERS

4.9.6 CONCLUSION

4.1 REIMBURSEMENT FRAMEWORK

4.10.1 REIMBURSEMENT STRUCTURES ACROSS ASIA PACIFIC

4.10.2 ROLE OF PUBLIC INSURANCE AND NATIONAL HEALTH POLICIES

4.10.3 PRIVATE INSURANCE AND OUT-OF-POCKET FINANCING

4.10.4 HEALTH TECHNOLOGY ASSESSMENT AND VALUE-BASED REIMBURSEMENT

4.10.5 CHALLENGES IN REIMBURSEMENT FOR CONGENITAL HEART DISEASE CARE

4.10.6 STRATEGIC CONSIDERATIONS FOR MARKET PARTICIPANTS

4.11 OPPORTUNITY MAP ANALYSIS

4.11.1 EXPANSION OF UNIVERSAL HEALTH COVERAGE AND PUBLIC FINANCING

4.11.2 INTEGRATION OF HEALTH TECHNOLOGY ASSESSMENT INTO REIMBURSEMENT

4.11.3 PUBLIC-PRIVATE PARTNERSHIPS TO MITIGATE FINANCIAL BARRIERS

4.11.4 ADDRESSING FRAGMENTATION IN DIGITAL HEALTH REIMBURSEMENT

4.11.5 STRATEGIC ALIGNMENT WITH VALUE-BASED CARE MODELS

4.11.6 STRENGTHENING EQUITABLE ACCESS ACROSS GEOGRAPHIC AND SOCIOECONOMIC LINES

4.11.7 BUILDING CAPACITY FOR REIMBURSEMENT POLICY DEVELOPMENT

4.11.8 CONCLUSION

4.12 SUPPLY CHAIN ECOSYSTEM

4.12.1 PROMINENT COMPANIES

4.12.2 SMALL & MEDIUM SIZE COMPANIES

4.12.3 END USERS

4.13 HEALTHCARE ECONOMY

4.13.1 HEALTHCARE EXPENDITURE

4.13.2 CAPITAL EXPENDITURE

4.13.3 CAPEX TRENDS

4.13.4 CAPEX ALLOCATION

4.13.5 FUNDING SOURCES

4.13.6 INDUSTRY BENCHMARKS

4.13.7 HEALTHCARE EXPENDITURE AS A PROPORTION OF GDP

4.13.8 HEALTHCARE SYSTEM STRUCTURE

4.13.8.1 PUBLIC AND PRIVATE SECTOR COMPOSITION

4.13.8.2 PRIMARY, SECONDARY, AND TERTIARY CARE STRUCTURE

4.13.8.3 REFERRAL AND CARE PATHWAYS

4.13.8.4 REGIONAL DISPARITIES

4.13.8.5 INTEGRATION OF DIGITAL AND TELEHEALTH SERVICES

4.13.8.6 IMPLICATIONS FOR THE CHD MARKET

4.13.9 GOVERNMENT POLICIES

4.13.9.1 HEALTH FINANCING AND REIMBURSEMENT POLICIES

4.13.9.2 REGULATORY AND LICENSING POLICIES

4.13.9.3 NATIONAL HEALTH PROGRAMS AND INITIATIVES

4.13.9.4 TECHNOLOGY ADOPTION AND DIGITAL HEALTH POLICIES

4.13.9.5 IMPLICATIONS FOR THE CHD MARKET

4.13.10 ECONOMIC DEVELOPMENT

4.13.10.1 GDP GROWTH AND HEALTHCARE INVESTMENT

4.13.10.2 INCOME LEVELS AND MARKET SEGMENTATION

4.13.10.3 HUMAN CAPITAL AND SKILLED WORKFORCE

4.13.10.4 INFRASTRUCTURE AND CAPITAL INVESTMENT

4.13.10.5 POLICY IMPLICATIONS AND ECONOMIC PLANNING

4.13.10.6 IMPLICATIONS FOR THE ASIA PACIFIC CHD MARKET

5 TARIFFS & IMPACT ON THE MARKET

5.1 CURRENT TARIFF RATE(S) IN TOP-5 COUNTRY MARKETS

5.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE

5.3 VENDOR SELECTION CRITERIA DYNAMICS

5.4 IMPACT ON SUPPLY CHAIN

5.4.1 RAW MATERIAL PROCUREMENT

5.4.2 MANUFACTURING AND PRODUCTION

5.4.3 LOGISTICS AND DISTRIBUTION

5.4.4 PRICE PITCHING AND POSITION OF MARKET

5.5 INDUSTRY PARTICIPANTS: PROACTIVE MOVES

5.5.1 SUPPLY CHAIN OPTIMIZATION

5.5.2 JOINT VENTURE ESTABLISHMENTS

5.6 IMPACT ON PRICES

 

6  REGULATORY COMPLIANCE

6.1 REGULATORY AUTHORITIES

6.2 REGULATORY CLASSIFICATIONS

6.3 REGULATORY SUBMISSIONS

6.3.1 COMPONENTS OF REGULATORY SUBMISSIONS

6.3.2 SUBMISSION PATHWAYS IN KEY APAC MARKETS

6.3.3 EXPEDITED AND SPECIAL SUBMISSION ROUTES

6.3.4 ELECTRONIC SUBMISSIONS AND DIGITAL PLATFORMS

6.3.5 STRATEGIC CONSIDERATIONS FOR MANUFACTURERS

6.4  INTERNATIONAL HARMONIZATION

6.4.1 HARMONIZATION FRAMEWORKS AND GLOBAL REGULATORY FORUMS

6.4.2 REGIONAL CONVERGENCE INITIATIVES IN ASIA PACIFIC

6.4.3 REGULATORY RELIANCE AND MUTUAL RECOGNITION

6.4.4 BENEFITS OF HARMONIZATION TO THE MEDICAL DEVICE INDUSTRY

6.4.5 CHALLENGES AND ONGOING ADVANCES

6.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

6.6 REGULATORY CHALLENGES AND STRATEGIES

6.6.1 REGULATORY CHALLENGES

6.6.2 REGULATORY STRATEGIES FOR MARKET ACCESS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING PREVALENCE OF CONGENITAL HEART DEFECTS IN NEWBORNS

7.1.2 TECHNOLOGICAL ADOPTION IN INTERVENTIONAL CARDIOLOGY AND DEVICE THERAPY

7.1.3 INCREASING AWARENESS AND EARLY DIAGNOSIS INITIATIVES

7.1.4 GROWTH IN HEALTHCARE INFRASTRUCTURE AND SPECIALIZED PAEDIATRIC CARDIAC UNITS

7.2 RESTRAINTS

7.2.1 HIGH COST FOR THE TREATMENT OF CONGENITAL HEART DISEASE

7.2.2 LIMITED ACCESS TO ADVANCED HEALTHCARE INFRASTRUCTURE

7.3 OPPORTUNITIES

7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE IN IMAGING INTERPRETATION AND RISK STRATIFICATION

7.3.2 SCALE-UP OF MINIMALLY INVASIVE TRANSCATHETER THERAPIES

7.3.3 INCREASED GOVERNMENT FUNDING AND PUBLIC-PRIVATE PARTNERSHIPS

7.4 CHALLENGES

7.4.1 SHORTAGE OF SKILLED PEDIATRIC CARDIOLOGISTS

7.4.2 REGULATORY HETEROGENEITY ACROSS ASIA-PACIFIC MARKETS

 

8 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)

8.1 OVERVIEW

8.2 TREATMENT

8.3 DIAGNOSTIC

8.4 ASIA-PACIFIC TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.4.1 INTERVENTIONAL DEVICES

8.4.2 SUPPORTIVE DEVICES

8.4.3 SURGICAL DEVICES

8.4.4 MEDICATION

8.4.5 OTHERS

8.5 ASIA-PACIFIC INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.5.1 SEPTAL OCCLUDERS

8.5.2 DELIVERY SYSTEMS

8.5.3 BALLOON CATHETERS

8.5.4 STENTS

8.6 ASIA-PACIFIC SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.6.1 ASD (ATRIAL SEPTAL DEFECT) OCCLUDERS

8.6.2 VSD (VENTRICULAR SEPTAL DEFECT) OCCLUDERS

8.7 ASIA-PACIFIC STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.7.1 DRUG-ELUTING STENTS

8.7.2 BARE-METAL STENTS

8.8 ASIA-PACIFIC SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.8.1 MONITORING SYSTEMS

8.8.2 INFUSION PUMPS

8.9 ASIA-PACIFIC SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.9.1 PEDIATRIC HEART VALVES

8.9.2 PEDIATRIC VENTRICULAR ASSIST DEVICES

8.9.3 GRAFTS & PATCHES

8.9.4 PEDIATRIC PACEMAKERS

8.9.5 DEFIBRILLATORS

 

8.1 ASIA-PACIFIC PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.10.1 BIOPROSTHETIC VALVES

8.10.2 MECHANICAL VALVES

8.11 ASIA-PACIFIC MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.11.1 ACE INHIBITORS

8.11.2 DIURETICS

8.11.3 BETA BLOCKERS

8.11.4 ANTICOAGULANTS

8.11.5 PROSTAGLANDIN ANALOGS

8.11.6 OTHERS

8.12 ASIA-PACIFIC DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

8.12.1 CARDIAC CATHETERIZATION LAB EQUIPMENT

8.12.2 ECHOCARDIOGRAPHY SYSTEMS

8.12.3 MRI SYSTEMS

8.12.4 X-RAY DEVICES

8.12.5 CT SCAN SYSTEMS

8.12.6 ELECTROCARDIOGRAPHY (ECG) DEVICES

8.13 ASIA-PACIFIC CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.13.1 ANGIOGRAPHY SYSTEMS

8.13.2 PRESSURE MONITORS

8.14 ASIA-PACIFIC ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.14.1 TRANSTHORACIC ECHOCARDIOGRAPHY

8.14.2 TRANSESOPHAGEAL ECHOCARDIOGRAPHY

8.14.3 FETAL ECHOCARDIOGRAPHY

8.15 ASIA-PACIFIC MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.15.1 CARDIAC MRI

8.15.2 WHOLE-BODY MRI

8.16 ASIA-PACIFIC CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.16.1 CARDIAC CT

8.16.2 ELECTRON BEAM CT

8.17 ASIA-PACIFIC ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.17.1 RESTING ECG

8.17.2 STRESS ECG

9 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE, 2018-2033 (USD THOUSANDS)

9.1 OVERVIEW

9.1.1 ACYANOTIC CONGENITAL HEART DISEASE

9.1.2 CYANOTIC CONGENITAL HEART DISEASE

9.1.3 COMPLEX CONGENITAL HEART DEFECTS

9.2 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

9.2.1 VENTRICULAR SEPTAL DEFECT (VSD)

9.2.2 ATRIAL SEPTAL DEFECT (ASD)

9.2.3 PULMONARY STENOSIS

9.2.4 PATENT DUCTUS ARTERIOSUS (PDA)

9.2.5 AORTIC STENOSIS

9.3 ASIA-PACIFIC VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.3.1 MEMBRANOUS VSD

9.3.2 MUSCULAR VSD

9.4 ASIA-PACIFIC ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.4.1 OSTIUM SECUNDUM ASD

9.4.2 OSTIUM PRIMUM ASD

9.5 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

9.5.1 TREATMENT

9.5.2 DIAGNOSTIC

9.6 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

9.6.1 TRANSPOSITION OF GREAT ARTERIES

9.6.2 TETRALOGY OF FALLOT

9.6.3 HYPOPLASTIC LEFT HEART SYNDROME

9.6.4 TRICUSPID ATRESIA

9.7 ASIA-PACIFIC TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.7.1 PULMONARY ATRESIA

9.7.2 OVERRIDING AORTA

9.7.3 RIGHT VENTRICULAR HYPERTROPHY

9.8 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

9.8.1 TREATMENT

9.8.2 DIAGNOSTIC

9.9 ASIA-PACIFIC COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

9.9.1 TREATMENT

9.9.2 DIAGNOSTIC

10 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSANDS)

10.1 OVERVIEW

10.1.1 ADULTS WITH CONGENITAL HEART DISEASE

10.1.2 NEONATES AND INFANTS (0–1 YEARS)

10.1.3 CHILDREN (1–12 YEARS)

10.1.4 ADOLESCENTS (13–18 YEARS)

11 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSANDS)

11.1 OVERVIEW

11.2 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

11.2.1 HOSPITALS

11.2.2 PEDIATRIC CARDIAC CENTERS

11.2.3 SPECIALTY CLINICS

11.2.4 DIAGNOSTIC LABORATORIES

11.2.5 RESEARCH & ACADEMIC INSTITUTES

11.2.6 HOMECARE SETTINGS

11.2.7 OTHER END USERS

11.3 ASIA-PACIFIC HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

11.3.1 PUBLIC

11.3.2 PRIVATE

12 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSANDS)

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 WHOLESALE DISTRIBUTORS

12.4 RETAIL SALES

12.5 ONLINE SALES

12.6 OTHERS

 

13 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET BY COUNTRIES

13.1 ASIA PACIFIC

13.1.1 CHINA

13.1.2 JAPAN

13.1.3 INDIA

13.1.4 SOUTH KOREA

13.1.5 AUSTRALIA

13.1.6 INDONESIA

13.1.7 THAILAND

13.1.8 TAIWAN

13.1.9 VIETNAM

13.1.10 MALAYSIA

13.1.11 SINGAPORE

13.1.12 PHILIPPINES

13.1.13 NEW ZEALAND

13.1.14 REST OF ASIA-PACIFIC

14 ASIA PACIFIC CONGENITAL HEAR DISEASE MARKET

14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

15 SWOT ANALYSIS

16 MEDICAL DEVICE COMPANY PROFILE

16.1 MEDTRONIC

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 PRODUCT PORTFOLIO

16.1.4 RECENT DEVELOPMENT

16.2 EDWARDS LIFESCIENCES CORPORATION

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 PRODUCT PORTFOLIO

16.2.4 RECENT DEVELOPMENT

16.3 TRIVITRON HEALTHCARE

16.3.1 COMPANY SNAPSHOT

16.3.2 PRODUCT PORTFOLIO

16.3.3 RECENT DEVELOPMENT

 

16.4 ARTIVION, INC.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENT

16.5 ABBOTT

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENT

16.6 BOSTON SCIENTIFIC CORPORATION

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 TERUMO CORPORATION

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 SHANGHAI MICROPORT SCIENTIFIC CORPORATION

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 LIFETECH SCIENTIFIC

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 LEPU MEDICAL TECHNOLOGY

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 W. L. GORE & ASSOCIATES INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENT

 

16.12 MERIL

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 LIVANOVA PLC

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT/SERVICE PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 B. BRAUN SE

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT/SERVICE PORTFOLIO

16.14.3 RECENT DEVELOPMENT

16.15 SIEMENS HEALTHINEERS AG

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT/SERVICE PORTFOLIO

16.15.4 RECENT DEVELOPMENT

16.16 KONINKLIJKE PHILIPS N.V.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT/SERVICE PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 GE HEALTHCARE

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT/SERVICE PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.18 GETINGE AB

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENT

16.19 INTEGER HOLDINGS CORPORATION (PARENT COMPANY OF OSCOR INC.)

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

 

16.2 NARANG MEDICAL LIMITED

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENT

17 PHARMA COMPANY PROFILE

17.1 NOVARTIS AG

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENT

17.2 PFIZER INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENT

17.3 ASTRAZENECA PLC

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENT

17.4 SUN PHARMACEUTICAL INDUSTRIES LTD.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENT

17.5 BRISTOL-MYERS SQUIBB (BMS)

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENT

17.6 ADVACARE PHARMA

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2 ASIA-PACIFIC TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 18 ASIA-PACIFIC VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 29 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 58 CHINA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 59 CHINA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 60 CHINA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 61 CHINA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 62 CHINA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 63 CHINA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 64 CHINA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 65 CHINA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 66 CHINA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 67 CHINA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 68 CHINA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 69 CHINA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 70 CHINA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 71 CHINA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 72 CHINA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 73 CHINA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 74 CHINA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 75 CHINA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 76 CHINA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 77 CHINA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 78 CHINA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 79 CHINA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 80 CHINA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 81 CHINA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 82 CHINA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 83 CHINA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 84 CHINA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 85 CHINA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 86 JAPAN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 87 JAPAN TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 88 JAPAN INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 89 JAPAN SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 90 JAPAN STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 91 JAPAN SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 92 JAPAN SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 93 JAPAN PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 94 JAPAN MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 95 JAPAN DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 96 JAPAN CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 97 JAPAN ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 98 JAPAN MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 99 JAPAN CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 100 JAPAN ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 101 JAPAN CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 102 JAPAN ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 103 JAPAN VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 104 JAPAN ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 105 JAPAN ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 106 JAPAN CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 107 JAPAN TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 JAPAN CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 109 JAPAN COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 110 JAPAN CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 111 JAPAN CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 112 JAPAN HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 113 JAPAN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 114 INDIA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 115 INDIA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 116 INDIA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 117 INDIA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 118 INDIA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 119 INDIA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 120 INDIA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 121 INDIA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 122 INDIA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 123 INDIA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 124 INDIA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 125 INDIA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 126 INDIA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 127 INDIA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 128 INDIA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 129 INDIA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 130 INDIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 131 INDIA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 132 INDIA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 133 INDIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 134 INDIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 135 INDIA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 136 INDIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 137 INDIA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 138 INDIA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 139 INDIA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 140 INDIA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 141 INDIA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 142 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 143 SOUTH KOREA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 144 SOUTH KOREA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 145 SOUTH KOREA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 146 SOUTH KOREA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 147 SOUTH KOREA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 148 SOUTH KOREA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 149 SOUTH KOREA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 150 SOUTH KOREA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 151 SOUTH KOREA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 152 SOUTH KOREA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 153 SOUTH KOREA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 SOUTH KOREA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 155 SOUTH KOREA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 156 SOUTH KOREA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 157 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 158 SOUTH KOREA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 159 SOUTH KOREA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 160 SOUTH KOREA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 161 SOUTH KOREA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 162 SOUTH KOREA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 163 SOUTH KOREA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 164 SOUTH KOREA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 165 SOUTH KOREA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 166 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 167 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 168 SOUTH KOREA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 169 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 170 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 171 AUSTRALIA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 172 AUSTRALIA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 173 AUSTRALIA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 174 AUSTRALIA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 175 AUSTRALIA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 AUSTRALIA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 177 AUSTRALIA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 178 AUSTRALIA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 179 AUSTRALIA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 180 AUSTRALIA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 181 AUSTRALIA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 182 AUSTRALIA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 183 AUSTRALIA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 184 AUSTRALIA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 185 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 186 AUSTRALIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 187 AUSTRALIA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 188 AUSTRALIA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 189 AUSTRALIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 190 AUSTRALIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 191 AUSTRALIA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 192 AUSTRALIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 193 AUSTRALIA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 194 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 195 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 196 AUSTRALIA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 197 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 198 INDONESIA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 199 INDONESIA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 200 INDONESIA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 201 INDONESIA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 202 INDONESIA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 203 INDONESIA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 204 INDONESIA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 205 INDONESIA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 206 INDONESIA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 207 INDONESIA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 208 INDONESIA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 209 INDONESIA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 210 INDONESIA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 211 INDONESIA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 212 INDONESIA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 213 INDONESIA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 214 INDONESIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 215 INDONESIA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 216 INDONESIA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 217 INDONESIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 218 INDONESIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 219 INDONESIA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 220 INDONESIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 221 INDONESIA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 222 INDONESIA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 223 INDONESIA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 224 INDONESIA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 225 INDONESIA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 226 THAILAND CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 227 THAILAND TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 228 THAILAND INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 THAILAND SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 230 THAILAND STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 231 THAILAND SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 232 THAILAND SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 233 THAILAND PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 234 THAILAND MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 235 THAILAND DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 236 THAILAND CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 237 THAILAND ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 238 THAILAND MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 239 THAILAND CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 240 THAILAND ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 241 THAILAND CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 242 THAILAND ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 243 THAILAND VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 244 THAILAND ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 245 THAILAND ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 246 THAILAND CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 247 THAILAND TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 248 THAILAND CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 249 THAILAND COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 250 THAILAND CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 251 THAILAND CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 252 THAILAND HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 253 THAILAND CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 254 TAIWAN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 255 TAIWAN TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 256 TAIWAN INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 257 TAIWAN SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 258 TAIWAN STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 259 TAIWAN SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 260 TAIWAN SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 261 TAIWAN PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 262 TAIWAN MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 263 TAIWAN DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 264 TAIWAN CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 265 TAIWAN ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 266 TAIWAN MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 267 TAIWAN CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 268 TAIWAN ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 269 TAIWAN CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 270 TAIWAN ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 271 TAIWAN VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 272 TAIWAN ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 273 TAIWAN ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 274 TAIWAN CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 275 TAIWAN TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 276 TAIWAN CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 277 TAIWAN COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 278 TAIWAN CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 279 TAIWAN CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 280 TAIWAN HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 281 TAIWAN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 282 VIETNAM CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 283 VIETNAM TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 284 VIETNAM INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 285 VIETNAM SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 286 VIETNAM STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 287 VIETNAM SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 288 VIETNAM SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 289 VIETNAM PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 290 VIETNAM MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 291 VIETNAM DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 292 VIETNAM CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 293 VIETNAM ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 294 VIETNAM MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 295 VIETNAM CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 VIETNAM ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 297 VIETNAM CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 298 VIETNAM ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 299 VIETNAM VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 300 VIETNAM ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 301 VIETNAM ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 302 VIETNAM CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 303 VIETNAM TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 304 VIETNAM CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 305 VIETNAM COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 306 VIETNAM CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 307 VIETNAM CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 308 VIETNAM HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 309 VIETNAM CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 310 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 311 MALAYSIA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 312 MALAYSIA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 313 MALAYSIA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 314 MALAYSIA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 315 MALAYSIA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 316 MALAYSIA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 317 MALAYSIA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 318 MALAYSIA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 319 MALAYSIA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 320 MALAYSIA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 321 MALAYSIA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 322 MALAYSIA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 323 MALAYSIA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 324 MALAYSIA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 325 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 326 MALAYSIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 327 MALAYSIA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 328 MALAYSIA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 329 MALAYSIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 330 MALAYSIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 331 MALAYSIA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 332 MALAYSIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 333 MALAYSIA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 334 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 335 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 336 MALAYSIA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 337 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 338 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 339 SINGAPORE TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 340 SINGAPORE INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 341 SINGAPORE SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 342 SINGAPORE STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 343 SINGAPORE SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 344 SINGAPORE SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 345 SINGAPORE PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 346 SINGAPORE MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 347 SINGAPORE DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 348 SINGAPORE CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 349 SINGAPORE ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 350 SINGAPORE MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 351 SINGAPORE CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 352 SINGAPORE ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 353 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 354 SINGAPORE ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 355 SINGAPORE VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 356 SINGAPORE ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 357 SINGAPORE ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 358 SINGAPORE CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 359 SINGAPORE TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 360 SINGAPORE CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 361 SINGAPORE COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 362 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 363 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 364 SINGAPORE HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 365 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 366 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 367 PHILIPPINES TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 368 PHILIPPINES INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 369 PHILIPPINES SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 370 PHILIPPINES STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 371 PHILIPPINES SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 372 PHILIPPINES SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 373 PHILIPPINES PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 374 PHILIPPINES MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 375 PHILIPPINES DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 376 PHILIPPINES CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 377 PHILIPPINES ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 378 PHILIPPINES MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 PHILIPPINES CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 380 PHILIPPINES ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 381 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 382 PHILIPPINES ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 383 PHILIPPINES VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 384 PHILIPPINES ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 385 PHILIPPINES ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 386 PHILIPPINES CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 387 PHILIPPINES TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 388 PHILIPPINES CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 389 PHILIPPINES COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 390 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 391 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 392 PHILIPPINES HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 393 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 394 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 395 NEW ZEALAND TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 396 NEW ZEALAND INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 397 NEW ZEALAND SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 398 NEW ZEALAND STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 399 NEW ZEALAND SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 400 NEW ZEALAND SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 401 NEW ZEALAND PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 402 NEW ZEALAND MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 403 NEW ZEALAND DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 404 NEW ZEALAND CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 405 NEW ZEALAND ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 406 NEW ZEALAND MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 407 NEW ZEALAND CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 408 NEW ZEALAND ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 409 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 410 NEW ZEALAND ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 411 NEW ZEALAND VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 412 NEW ZEALAND ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 413 NEW ZEALAND ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 414 NEW ZEALAND CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 415 NEW ZEALAND TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 416 NEW ZEALAND CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 417 NEW ZEALAND COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 418 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 419 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 420 NEW ZEALAND HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 421 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 422 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 423 REST OF ASIA-PACIFIC TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 424 REST OF ASIA-PACIFIC INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 425 REST OF ASIA-PACIFIC SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 426 REST OF ASIA-PACIFIC STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 427 REST OF ASIA-PACIFIC SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 428 REST OF ASIA-PACIFIC SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 429 REST OF ASIA-PACIFIC PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 430 REST OF ASIA-PACIFIC MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 431 REST OF ASIA-PACIFIC DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)

TABLE 432 REST OF ASIA-PACIFIC CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 433 REST OF ASIA-PACIFIC ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 434 REST OF ASIA-PACIFIC MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 435 REST OF ASIA-PACIFIC CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 436 REST OF ASIA-PACIFIC ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 437 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)

TABLE 438 REST OF ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 439 REST OF ASIA-PACIFIC VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 440 REST OF ASIA-PACIFIC ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 441 REST OF ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 442 REST OF ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)

TABLE 443 REST OF ASIA-PACIFIC TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 444 REST OF ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 445 REST OF ASIA-PACIFIC COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)

TABLE 446 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)

TABLE 447 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)

TABLE 448 REST OF ASIA-PACIFIC HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 449 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

List of Figure

FIGURE 1 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: COUNTRYWISE MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: MULTIVARIATE MODELLING

FIGURE 8 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: MARKET END-USER COVERAGE GRID

FIGURE 11 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: SEGMENTATION

FIGURE 12 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: EXECUTIVE SUMMARY

FIGURE 13 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: STRATEGIC DECISIONS

FIGURE 14 TWO SEGMENTS COMPRISE THE DOMINICAN REPUBLIC ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE

FIGURE 15 RISING PREVALENCE OF CONGENITAL HEART DEFECTS IN NEWBORNS EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC CONGENITAL HEART DISEASE MARKET FROM 2026 TO 2033

FIGURE 16 THE TYPE 2 ENDOSCOPIC HEMOSTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC CONGENITAL HEART DISEASE MARKET IN 2026 & 2033

FIGURE 17 DROC ANALYSIS

FIGURE 18 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2025

FIGURE 19 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY PRODUCT TYPE, 2026-2033 (USD THOUSAND)

FIGURE 20 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY PRODUCT TYPE, CAGR (2026-2033)

FIGURE 21 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 22 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE, 2025

FIGURE 23 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISEASE TYPE, 2026-2033 (USD THOUSAND)

FIGURE 24 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISEASE TYPE, CAGR (2026-2033)

FIGURE 25 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 26 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2025

FIGURE 27 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY AGE GROUP, 2026-2033 (USD THOUSAND)

FIGURE 28 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY AGE GROUP, CAGR (2026-2033)

FIGURE 29 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER, 2025

FIGURE 31 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY END USER, 2026-2033 (USD THOUSAND)

FIGURE 32 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY END USER, CAGR (2026-2033)

FIGURE 33 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2025

FIGURE 35 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)

FIGURE 36 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2026-2033)

FIGURE 37 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET SNAPSHOTS

FIGURE 39 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: COMPANY SHARE 2025 (%)

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Industry Related Reports

Browse Related Pages

Testimonial
Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future
Request for TOC Speak to Analyst Free Sample Report Inquire Before Buy Now
Request a Call
Please select country
Please enter Contact No.
Please enter job tital
Please enter company name
Request for Demo
Please select country
Please enter Contact No.
Please enter job tital
Please enter company name
Office Number 402, Amanora
Chambers, Magarpatta Road, Hadapsar
Pune – 411028.

Reports

Market Insights

Support

Solutions

DMCA Protected © DataBridge - All Rights Reserved.

We Accept Payment